中重度高血压降压药物联合阿托伐他汀治疗的疗效观察

Therapeutic Effects of Antihypertension Combined with Atorvastatin in Moderate and Severe Hypertensive Patients

目的:研究中重度高血压人群降压治疗中联合使用阿托伐他汀的治疗疗效。方法:60名中重度高血压患者随机分为两组:即苯磺酸氨氯地平5mg/日+厄贝沙坦150mg/日与阿托伐他汀20mg/日(治疗组)和苯磺酸氨氯地平5mg/日+厄贝沙坦150mg/日(对照组),在基线、半年及一年后分别测量血压、血脂、高敏C反应蛋白(Hs-CRP)、心绞痛、非致死性心肌梗死及脑梗死发生情况。结果:1年后,治疗组TC由5.36mmol/L下降至4.56mmol/L,LDL-c由3.51mmol/L下降至2.5mmol/L,对照组TC由5.44mmol/L下降至5.28mmol/L,LDL-c由3.46mmol/L上升至3.54mmol/L(组间比较P<0.05)。1年后治疗组Hs-CRP从2.03降至1.53mg/L,而对照组无显著变化(P<0.05),治疗组心绞痛、非致死性心肌梗死及脑梗死的发生较对照组有下降,但P>0.05。结论:中重度高血压患者合并轻度高胆固醇血症及其他心血管危险因素时,在联合降压的同时强化使用他汀类药物可显著降低TC、LDL-c及Hs-CRP,对减少心血管事件的发生可能是有益的。

Objective:To observe the therapeutic effects of antihypertension combined with atorvastatin in moderate and severe hypertensive patients.Methods:60 moderate and severe hypertensive patients were randomly divided into atorvastatin group(Amlodipine benzenesulfonate 5mg+ Irbesartan 150 mg +atorvastatin 20 mg per day)and control group(Amlodipine benzenesulfonate 5mg+ Irbesartan 150 mg per day)and followed up for one year.Blood pressure,lipid profile,hs-CRP,angina pectoris,non-fatal myocardial infarction and cerebral infarction were recorded before and half a year and the end of one year treatment in all patients.Results:one year after treatment,TC decreased from 5.36 to 4.56 mmol/L in atorvastatin group(P<0.05)and almost had no change in control group,LDL-C decreased from 3.51 to 2.5mmol/L in treatment group(P<0.05),and increased from 3.46 to 3.54mmol/L in control group,Hs-CRP decreased from 2.03 to 1.53mg/L in atorvastatin group(P<0.05)and almost had no change in control group.After one year's treatment,Hs-CRP,TC,TG,LDL-C were significantly lower in atorvastatin group than those in control group(P<0.05).The incidence of angina pectoris,non-fatal myocardial infarction and cerebral infarction was slightly decreased in atorvastatin group compared with control group,but it was not significant(P>0.05).Conclusions:It seems beneficial to combine antihypertension with atorvastatin in moderate and severe hypertensive patients with mild hyperlipemia and other cardiovascular risk factors for lowing TC,LDL-c and Hs-CRP.